The Conversation (0)
Lixte Biotechnology Enrolls First Patients in LB-100 Study
Dec. 04, 2019 08:44AM PST
Pharmaceutical InvestingThe first two patients out of eight have been enrolled testing its lead product, LB-100, in brain tumor patients.
Lixte Biotechnology (OTCQB:LIXT) has announced that the National Cancer Institute (NCI) has enrolled the first two out of eight patients testing its lead product LB-100 in brain tumor patients.
As quoted in the press release:
This study is being conducted by NCI under a Cooperative Research and Development Agreement (CRADA) with Lixte.
Dr. John S. Kovach, CEO of Lixte, said, “Primary malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug, temozolomide has been the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme, GBM) for decades with some further benefit gained by the addition of one or more anti-cancer drugs but without major advances in overall survival for the majority of patients. In animal models of GBM, Lixte’s novel protein phosphatase inhibitor, LB-100, enhances the effectiveness of both radiation, temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain is not known. Unfortunately, many drugs potentially useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.
The NCI study is designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove one or more tumors will receive one dose of LB-100 prior to surgery and have blood and tumor tissue analyzed for the amount of LB-100 present and to determine whether the cells in the tumors show the biochemical changes expected to be present if LB-100 reaches its molecular target. The goal is to obtain data in up to eight patients. Thanks to the innovative design of the NCI study, data from so few patients should be sufficient to provide a sound rationale for a conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment regimen for GBMs.”
